Clinical reference Biomarker Directory
Back to directory

Porphobilinogen Deaminase

Established

Porphobilinogen deaminase deficiency causes acute intermittent porphyria, diagnosed via enzyme or genetic testing.

Also known as HMBS hydroxymethylbilane synthase PBGD
In plain language

This enzyme is part of the pathway that makes heme (a component of blood). When it's deficient, attacks of severe abdominal pain and nervous system symptoms can occur, often triggered by certain medications or fasting. Genetic testing helps identify family members who carry the gene before they ever have an attack.

Biomarker & context

Porphobilinogen deaminase (also called hydroxymethylbilane synthase) is an enzyme in the heme synthesis pathway; its deficiency causes acute intermittent porphyria (AIP), the most common acute porphyria.

What it indicates

Low enzyme activity supports AIP diagnosis in a patient with the classic triad of severe abdominal pain, neuropsychiatric symptoms, and dark/reddish urine during an acute attack, often triggered by certain medications, fasting, alcohol, or hormonal changes.

Diagnosis & clinical testing

Measured via red blood cell enzyme activity assay, though genetic testing (HMBS gene sequencing) is increasingly used for definitive diagnosis and, importantly, for screening asymptomatic family members who carry the gene but haven't yet had an attack.

Guiding treatment

Acute attacks are treated with intravenous hemin and glucose loading to suppress heme pathway overactivity; patients are counseled to avoid known triggers (certain drugs, fasting, alcohol), and genetically confirmed carriers receive counseling even if asymptomatic.

Clinical significance

Genetic testing increasingly used for definitive diagnosis and identifying asymptomatic carrier family members.

References
  1. General hematology/genetics reference literature on acute intermittent porphyria diagnosis and management.